Abstract
Objectives - The present investigation was aimed at establishing whether interferon (IFN)-β would induce the synthesis of autoantibodies in patients affected by multiple sclerosis (MS). Materials and methods - The titres of different autoantibodies were measured in a group of 68 relapsing-remitting MS patients before and during treatment with human recombinant IFN-β(1a) (3 MIU or 9 MIU subcutaneously 3xa week). ANA, anti-thyroid, anticardiolipin serum autoantibodies were assayed in all cases: when patients were found positive to ANA>1: 40, they were also tested for anti-DNA and anti-ENA antibodies. Results - No increase was found in autoantibodies synthesis during 6 months of r-hIFNβ(1a) therapy, either at low or high dosages. The percentage of patients positive to different types of autoantibodies varied between 0 and 29%, which are values similar to those already reported in untreated MS patients. Conclusion - Our data indicate that the short-term use of IFN-β(1a) in MS is safe in terms of the induction of humoral autoimmune responses: however, further follow-up is needed to confirm these findings during long-term treatments.
| Original language | English |
|---|---|
| Pages (from-to) | 372-374 |
| Number of pages | 3 |
| Journal | Acta Neurologica Scandinavica |
| Volume | 96 |
| Issue number | 6 |
| Publication status | Published - 1997 |
Fingerprint
Keywords
- ANA
- Anti-cardiolipin
- Anti-thyroid
- Interferon β
- Multiple sclerosis
ASJC Scopus subject areas
- Clinical Neurology
- Neuroscience(all)
Cite this
No increase of serum autoantibodies during therapy with recombinant human interferon-β(1a) in relapsing-remitting multiple sclerosis. / Colosimo, C.; Pozzilli, C.; Frontoni, M.; Farina, D.; Koudriavtseva, T.; Gasperini, C.; Salvetti, M.; Valesini, G.
In: Acta Neurologica Scandinavica, Vol. 96, No. 6, 1997, p. 372-374.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - No increase of serum autoantibodies during therapy with recombinant human interferon-β(1a) in relapsing-remitting multiple sclerosis
AU - Colosimo, C.
AU - Pozzilli, C.
AU - Frontoni, M.
AU - Farina, D.
AU - Koudriavtseva, T.
AU - Gasperini, C.
AU - Salvetti, M.
AU - Valesini, G.
PY - 1997
Y1 - 1997
N2 - Objectives - The present investigation was aimed at establishing whether interferon (IFN)-β would induce the synthesis of autoantibodies in patients affected by multiple sclerosis (MS). Materials and methods - The titres of different autoantibodies were measured in a group of 68 relapsing-remitting MS patients before and during treatment with human recombinant IFN-β(1a) (3 MIU or 9 MIU subcutaneously 3xa week). ANA, anti-thyroid, anticardiolipin serum autoantibodies were assayed in all cases: when patients were found positive to ANA>1: 40, they were also tested for anti-DNA and anti-ENA antibodies. Results - No increase was found in autoantibodies synthesis during 6 months of r-hIFNβ(1a) therapy, either at low or high dosages. The percentage of patients positive to different types of autoantibodies varied between 0 and 29%, which are values similar to those already reported in untreated MS patients. Conclusion - Our data indicate that the short-term use of IFN-β(1a) in MS is safe in terms of the induction of humoral autoimmune responses: however, further follow-up is needed to confirm these findings during long-term treatments.
AB - Objectives - The present investigation was aimed at establishing whether interferon (IFN)-β would induce the synthesis of autoantibodies in patients affected by multiple sclerosis (MS). Materials and methods - The titres of different autoantibodies were measured in a group of 68 relapsing-remitting MS patients before and during treatment with human recombinant IFN-β(1a) (3 MIU or 9 MIU subcutaneously 3xa week). ANA, anti-thyroid, anticardiolipin serum autoantibodies were assayed in all cases: when patients were found positive to ANA>1: 40, they were also tested for anti-DNA and anti-ENA antibodies. Results - No increase was found in autoantibodies synthesis during 6 months of r-hIFNβ(1a) therapy, either at low or high dosages. The percentage of patients positive to different types of autoantibodies varied between 0 and 29%, which are values similar to those already reported in untreated MS patients. Conclusion - Our data indicate that the short-term use of IFN-β(1a) in MS is safe in terms of the induction of humoral autoimmune responses: however, further follow-up is needed to confirm these findings during long-term treatments.
KW - ANA
KW - Anti-cardiolipin
KW - Anti-thyroid
KW - Interferon β
KW - Multiple sclerosis
UR - http://www.scopus.com/inward/record.url?scp=0031450321&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031450321&partnerID=8YFLogxK
M3 - Article
C2 - 9449474
AN - SCOPUS:0031450321
VL - 96
SP - 372
EP - 374
JO - Acta Neurologica Scandinavica
JF - Acta Neurologica Scandinavica
SN - 0001-6314
IS - 6
ER -